Compare Amphastar Pharmaceuticals Inc (AMPH) vs Core and Main Inc (CNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Core and Main Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Core and Main Inc trades at $46.73 (market cap $8.67B). The key difference: Core and Main Inc is far larger — about 10× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | CNM | |
|---|---|---|
Market Cap | $863.95M | $8.67B |
Sector | Health | Technology |
52-Week High | $30.81 | $66.98 |
52-Week Low | $16.87 | $42.37 |
Enterprise Value | $1.26B | $10.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Core & Main (CNM) trades at $46.55, up 2.33% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 23.73% ROE and 5.87% net margin, supported by resilient municipal demand. Recent news highlights institutional activity, including CalSTRS increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is mixed: analyst consensus leans bullish with 57% buy ratings, but technical indicators suggest near-term pressure. Key risks include high debt levels and residential market weakness. Upside hinges on margin expansion and FY26 revenue guidance of $7.8–7.9B (Business Wire, 2026-06-25).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
